Examinant per Autoria "Albanell Mestres, Joan"
Resultats per pàgina
Opcions d'ordenació
Ítem Accés Obert A PAM50-based chemoendocrine score for hormone receptor-positive breast cancer with an intermediate risk of relapse(American Association for Cancer Research (AACR), 2017) Prat, Aleix; Alba, Emilio; Albanell Mestres, Joan
Ítem Accés Obert A SNAIL1-SMAD3/4 transcriptional repressor complex promotes TGF-beta mediated epithelial-mesenchymal transition(Nature Research, 2009) Vincent, Theresa; Neve, Etienne P.A.; Johnson, Jill R.; Kukalev, Alexander; Rojo, Federico; Albanell Mestres, Joan; Pietras, Kristian; Virtanen, Ismo; Philipson, Lennart; Leopold, Philip L.; Crystal, Ronald G.; García de Herreros, Antonio; Moustakas, Aristidis; Petterson, Ralf F.; Fuxe, Jonas
Ítem Accés Obert Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer(Nature Publishing Group, 2016) Van Emburgh, Beth O.; Vidal Barrull, Joana; Bellosillo Paricio, Beatriz; Albanell Mestres, Joan; Montagut Viladot, Clara; Bardelli, Alberto
Ítem Només Metadades Acquired resistance to the anti-EFGR monoclonal antibody cetuximab in colorectal cancer(Universitat Pompeu Fabra, 2012-10-03T11:54:32Z) Dalmases Massegú, Alba; Albanell Mestres, Joan; Montagut Viladot, Clara; Universitat Pompeu Fabra. Departament de Ciències Experimentals i de la Salut
Ítem Accés Obert Biomarkers in breast cancer: A consensus statement by the Spanish Society of Medical Oncology and the Spanish Society of Pathology(SpringerOpen, 2018) Colomer, Ramon; Aranda-Lopez, Ignacio; Albanell Mestres, Joan; García-Caballero, Tomás; Ciruelos, Eva; Lopez-García, M. A.; Cortés, Javier; Rojo, Federico; Martín, M.; Palacios-Calvo, J.
Ítem Accés Obert Broad consensus on the optimal sequence for the systemic treatment of metastatic breast cancer: results from a survey of spanish medical oncologists(Taylor & Francis, 2019) Sánchez-Rovira, Pedro; Zamora, Pilar; Salvador-Bofill, Javier; Morales, Serafín; Martínez-Jáñez, Noelia; Martínez-de-Dueñas, Eduardo; Lluch, Ana; Illarramendi, José Juan; Gómez-Pardo, Patricia; Gavilá Gregori, Joaquín; García-Palomo, Andrés; García-Mata, Jesús; Fernández, Yolanda; del Barco, Sonia; de Juan, Ana; Ciruelos, Eva; Chacón, José Ignacio; Calvo, Lourdes; Barnadas, Agustí; Albanell Mestres, Joan
Ítem Accés Obert Budget impact analysis of bevacizumab biosimilars for cancer treatment in adult patients in Spain(BMJ Publishing Group, 2021) Calleja, Miguel Angel; Albanell Mestres, Joan; Aranda, Enrique; García-Foncillas, Jesús; Feliu, Anna; Rivera, Fernando; Oyagüez, Itziar; Salinas-Ortega, Laura; Soto Alvarez, Javier
Ítem Accés Obert Cancer bioMarkers database(Universitat Pompeu Fabra, 2016-10-17) Tamborero Noguera, David; Rubio Pérez, Carlota; Déu Pons, Jordi; Schroeder, Michael Philipp, 1986-; Vivancos Prellezo, Ana; Rovira Guerín, Ana; Tusquets, Ignasi; Albanell Mestres, Joan; Rodon, Jordi; Tabernero Cartula, Josep; Dienstmann, Rodrigo; González-Pérez, Abel; López Bigas, Núria
Ítem Accés Obert Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations(BioMed Central, 2018) Tamborero Noguera, David; Rubio Pérez, Carlota, 1990-; Déu Pons, Jordi; Schroeder, Michael Philipp, 1986-; Vivancos Prellezo, Ana; Rovira Guerín, Ana; Tusquets Trias de Bes, Ignacio; Albanell Mestres, Joan; Rodon, Jordi; Tabernero Cartula, Josep; Torres, Carmen de; Dienstmann, Rodrigo; González-Pérez, Abel; López Bigas, Núria
Ítem Només Metadades Cancer-associated fibroblasts and response to anti-HER2 monoclonal antibodies in breast cancer(Universitat Pompeu Fabra, 2020-01-21T17:22:36Z) Guardia Valenzuela, Cristina; Albanell Mestres, Joan; Rovira Guerín, Ana; Universitat Pompeu Fabra. Departament de Ciències Experimentals i de la Salut
Ítem Accés Obert CIP2A as a key regulator for AKT phosphorylation has partial impact determining clinical outcome in breast cancer(MDPI, 2022) Luque, Melani; Cristóbal, Ion; Sanz Álvarez, Marta; Santos, Andrea; Zazo, Sandra; Eroles, Pilar; Arpí Llucià, Oriol; Rovira Guerín, Ana; Albanell Mestres, Joan; Madoz-Gúrpide, Juan; García-Foncillas, Jesús; Rojo, Federico
Ítem Accés Obert Contribution of trastuzumab to the prognostic improvement of HER2-positive early breast cancer in Spain: an estimation of life years and disease-free life years gained since its approval(Impact Journals, 2019) Ciruelos, Eva; Alba, Emilio; López, Rafael; Lluch, Ana; Martín, Miguel; Arroyo, Isabel; Navarro, Beatriz; Carcedo, David; Colomer, Ramon; Albanell Mestres, Joan
Ítem Accés Obert Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer(American Association for Cancer Research (AACR), 2017) Sabbaghi Mehrjardi, Mohammad Ali; Gil Gómez, Gabriel; Guardia Laguarta, Cristina; Servitja Tormo, Sonia; Arpí Llucià, Oriol; Menendez Romero, Silvia; Arumí, Montserrat; Serrano, Laia; Salido Galeote, Marta; Muntasell i Castellví, Aura, 1972-; Martínez-García, Maria; Tusquets Trias de Bes, Ignacio; Rovira Guerín, Ana; Albanell Mestres, Joan
Ítem Accés Obert Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-κB target genes in human breast cancer(Impact Journals, 2014) Dalmases Massegú, Alba, 1982-; González González, Irene; Menendez Romero, Silvia; Arpí Llucià, Oriol; Corominas Torres, Josep Maria; Servitja Tormo, Sonia; Tusquets Trias de Bes, Ignacio; Chamizo, Cristina; Rincón, Raúl; Espinosa Blay, Lluís; Bigas Salvans, Anna; Eroles, Pilar; Furriol, Jessica; Lluch, Ana; Rovira Guerín, Ana; Albanell Mestres, Joan; Rojo, Federico
Ítem Accés Obert Defining the optimal sequence for the systemic treatment of metastatic breast cancer.(Springer, 2017) Albanell Mestres, Joan; iMolins, A. B.; Martínez, L. C.; López-Muñiiz, J. I. C.; Gil, E. C.; Juan Ferré, A. de; Barco Berrón, Sonia del; Pérez, Y. F.; Mata, J. G.; Palomo, A. G.; Gregori, J. G.; Pardo, P. G.; Mañas, J. J. I.; Hernández, A. L.; Dueñas-Espín, Iván, 1979-; Jáñez, N. M.; Murillo, S. M.; Bofill, Javier Salvador; Auñón, Pilar Zamora; Sánchez-Rovira, Pedro
Ítem Accés Obert Derived neutrophil-to-lymphocyte ratio predicts pathological complete response to neoadjuvant chemotherapy in breast cancer(Frontiers, 2022) Ocaña, Alberto; Albanell Mestres, Joan; Gianni, Luca
Ítem Accés Obert Distinct GSDMB protein isoforms and protease cleavage processes differentially control pyroptotic cell death and mitochondrial damage in cancer cells(Nature Research, 2023) Oltra Sanchis, Sara; Albanell Mestres, Joan; Moreno-Bueno, Gema
Ítem Accés Obert Enhanced MAF Oncogene Expression and Breast Cancer Bone Metastasis.(Oxford Open , 2015) Pavlovic, Milica, 1985-; Arnal-Estapé, Anna ; Rojo, Federico; Bellmunt, Anna ; Tarragona, Maria ; Guiu, Marc; Planet, Evarist; Garcia-Albéniz, Xabier; Morales, Mònica; Urosevic, Jelena ; Gawrzak, Sylwia ; Rovira Guerín, Ana; Prat, Aleix; Nonell Mazelon, Lara, 1972-; Lluch, Ana; Jean-Mairet, Joël ; Coleman, Robert ; Albanell Mestres, Joan; Gomis, Roger R.
Ítem Accés Obert Enhancing human NK cell antitumor function by knocking out SMAD4 to counteract TGFβ and activin A suppression(Nature Research, 2025) Rea, Anna; Santana-Hernández, Sara; Villanueva, Javier; Sanvicente-García, Marta; Cabo, Mariona, 1991-; Suárez Olmos, Jesús; Quimis, Fabricio; Qin, Mengjuan; Llorens, Eduard; Blasco-Benito, Sandra; Alari-Pahissa, Elisenda; Celià-Terrassa, Toni; Montagut Viladot, Clara; Albanell Mestres, Joan; Güell Cargol, Marc, 1982-; López-Botet, M. (Miguel); Muntasell i Castellví, Aura, 1972-
Ítem Accés Obert Evolución de la DMO durante el tratamiento con inhibidores de aromatasa y su relación con el gen CYP11A1: estudio prospectivo de la cohorte B-ABLE(Sociedad Española de Investigación Ósea y del Metabolismo Mineral, 2015) Rodríguez Sanz, Maria, 1984-; Prieto-Alhambra, Daniel; Servitja Tormo, Sonia; Garcia Giralt, Natàlia; Garrigós, Laia; Albanell Mestres, Joan; Martinez-García, Maria; González, I.; Martos, Tamara; Díez Pérez, Adolfo; Tusquets Trias de Bes, Ignacio; Nogués Solan, Francesc Xavier